Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03169335 |
|
Recruitment Status :
Completed
First Posted : May 30, 2017
Last Update Posted : August 24, 2018
|
Sponsor:
Qilu Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Qilu Pharmaceutical Co., Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | June 23, 2018 |
| Actual Study Completion Date : | July 13, 2018 |